Thus, targeting the constitutive binding of HuR to caspase-2 mRNA may represent a promising therapeutic approach for sensitizing colorectal carcinoma cells to currently used anti-tumor therapies. This evidence concerns the gene ELAVL1 and colorectal carcinoma.